查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
血液和血漿成分市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按產品、按應用、最終用戶、公司和地區細分
市場調查報告書
商品編碼
1321035

血液和血漿成分市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按產品、按應用、最終用戶、公司和地區細分

Blood & Plasma Components Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Products, By Application, By End User, By company and By Region
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計全球血液和血漿成分市場在2023-2027年預測期內將出現令人印象深刻的成長。主要因素包括手術量的增加、創傷和道路事故發生率的激增，以及患有包括癌症在內的慢性病的人數的增加，這些都抑制了市場的成長。血液是一種維持生命的液體，流經全身，為身體組織提供營養、電解質、激素、抗體和維生素。血漿是血液的一部分，本質上是水性的；它含有鹽和蛋白質，其中懸浮有血小板、白細胞和紅細胞。支持市場成長的其他因素包括，人們對捐血重要性的認知不斷提高、患者人數較多、政府舉措、增加對研發活動的投資、各個血液組織開展的多次捐血活動、老年人口基數的增加、研發活動的增加和技術進步。此外，市場參與者採取的合作夥伴關係和產品發布等戰略舉措促進市場的成長。

創傷和道路事故的發生率不斷增加

創傷和道路事故發生率的增加是推動市場成長的重要因素。有時，人們會遭受出血等創傷；血液量減少，身體無法足夠快地補充。一項調查顯示，2018年，每年約有6萬名美國人死於失血或失血。此外，由於交通事故數量的增加，體內失血過多，增加了對輸血或血漿以防止出血的需求。因此，這些情況又促進了全球血液和血漿成分市場的成長。根據世界衛生組織的研究，2020年，全球每年有近150萬人因道路交通傷害死亡。

血液疾病和手術頻率上升

全球出血性疾病發病率的不斷上升和手術數量的增加推動市場的成長。 A 型和 B 型血友病以及von Willebrand氏病是最常見的出血性疾病。例如，2019年，全球有195,263人被診斷患有血友病，80,302人被診斷患有von Willebrand氏病。除此之外，手術病例的增加推動市場的成長，因為手術過程中會流失大量血液，這增加了需要輸血的機會。此外，貧血患者對輸血的需求也會增加。例如，全球每年進行約3.1億例大手術，其中5000萬例在美國，2000萬例在歐洲。

擴大採用無機成長策略

合併、合作、收購和夥伴關係等各種無機成長戰略支持市場的成長。例如，威斯康星州血液中心與 SysLogic Inc. 合作，研究如何利用 RFID 技術來提高患者在採集和輸注血液製品時的安全性。同樣，2018年，Invitrx Inc. 推出了一種臍帶血血漿產品，其中含有促進可塑性的蛋白質，可能具有抗衰老作用，可增加神經發生和認知功能。

市場細分

全球血液和血漿成分市場分為產品、應用、最終用戶和公司。根據產品，市場分為紅血球濃厚液、血小板產品、冷凍血漿和血漿衍生產品。根據血漿衍生產品，市場進一步分為免疫球蛋白、白蛋白、濃縮凝血因子等。根據應用，市場分為血液學、實體瘤管理等。根據血液學，市場進一步分為血紅蛋白病、血液惡性腫瘤治療、凝血病等。根據最終用戶，市場分為醫院和診所、診斷實驗室等。就國家而言，由於美國慢性病和手術數量不斷增加，預計在預測期內美國將成為一個利潤豐厚的市場。

市場參與者

CSL Limited、Grifols SA、ADMA Biologics, Inc.、Takeda Pharmaceutical Company Limited、Octapharma AG、Kedrion SpA、Emergent BioSolutions Inc.、Bio Products Laboratory Ltd.、LFB SA 和Versiti, Inc. 是在這些市場領域營運的一些領先公司。

可用的客製化

根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。本報告可以使用以下自定義選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球血液和血漿成分市場的影響

第5章：客戶之聲

第6章：全球血液和血漿成分市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 副產品（紅血球濃厚液、血小板產品、冷凍血漿、血漿衍生產品）
    • 按應用（血液學、實體瘤治療、其他）
    • 按最終用戶（醫院和診所、診斷實驗室、其他）
    • 按公司分類 (2021)
    • 按地區
  • 市場地圖

第7章：北美血液和血漿成分市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 副產品（紅血球濃厚液、血小板產品、冷凍血漿、血漿衍生產品）
    • 按應用（血液學、實體瘤治療、其他）
    • 按最終用戶（醫院和診所、診斷實驗室、其他）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第8章：歐洲血液和血漿成分市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 副產品（紅血球濃厚液、血小板產品、冷凍血漿、血漿衍生產品）
    • 按應用（血液學、實體瘤治療、其他）
    • 按最終用戶（醫院和診所、診斷實驗室、其他）
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章：亞太地區血液和血漿成分市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 副產品（紅血球濃厚液、血小板產品、冷凍血漿、血漿衍生產品）
    • 按應用（血液學、實體瘤治療、其他）
    • 按最終用戶（醫院和診所、診斷實驗室、其他）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第10章：南美血液和血漿成分市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 副產品（紅血球濃厚液、血小板產品、冷凍血漿、血漿衍生產品）
    • 按應用（血液學、實體瘤治療、其他）
    • 按最終用戶（醫院和診所、診斷實驗室、其他）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲血液和血漿成分市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 副產品（紅血球濃厚液、血小板產品、冷凍血漿、血漿衍生產品）
    • 按應用（血液學、實體瘤治療、其他）
    • 按最終用戶（醫院和診所、診斷實驗室、其他）
    • 按國家/地區
  • MEA：國家分析
    • 南非 血液和血漿成分
    • 沙烏地阿拉伯 血液和血漿成分
    • 阿拉伯聯合大公國血液和血漿成分

第12章：市場動態

  • 促進因素
  • 挑戰

第13章：市場趨勢與發展

第14章：競爭格局

  • CSL Limited
  • Grifols S.A.
  • ADMA Biologics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A
  • Emergent BioSolutions Inc.
  • Bio Products Laboratory Ltd.
  • LFB S.A.
  • Versiti, Inc.

第15章：戰略建議

簡介目錄
Product Code: 12989

The global blood & plasma components market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include the growing volume of surgeries, the surge in the prevalence of trauma and road accidents, and the increase in the number of people from chronic conditions, including cancer are curbing the growth of the market. Blood is a life-sustaining fluid that flows throughout the body, giving nourishment, electrolytes, hormones, antibodies, and vitamins to body tissues. Plasma is a part of the blood which is aqueous in nature; it contains salt and proteins in which platelets, white blood cells, and red blood cells are suspended. The other factors supporting the market's growth are, rising awareness associated with the significance of blood donations, high patient pool, government initiatives, increasing investments for research and development activities, several blood donation campaigns undertaken by various blood organizations, rise in the elderly population base, rise in R&D activities, and technological advancements. Also, the strategic initiatives such as partnerships and product launches undertaken by the market players are augmenting the growth of the market.

Increasing Occurrence of Trauma and Road Accidents

The growing incidence of trauma and road accidents is a significant factor propelling the growth of the market. At times, people suffer from traumas such as hemorrhage; the amount of blood present gets reduced and cannot be replaced fast enough by the body. According to a review, in 2018, approximately 60,000 Americans died from hemorrhaging or blood loss every year. Also, owing to the rise in the number of road accidents, excessive blood loss from the body is raising the demand for blood or plasma transfusion to prevent bleeding. Thus, in turn, these situations are augmenting the growth of the blood and plasma component market globally. According to WHO research, in 2020, nearly 1.5 million people died every year due to road traffic injuries around the globe.

Rising Frequency of Blood Diseases and Surgeries

The growing incidences of bleeding disorders and the rising number of surgeries across the globe are bolstering the growth of the market. Hemophilia A and B and von Willebrand disease are the most common bleeding disorders. For instance, in 2019, 195,263 people globally were diagnosed with hemophilia, and 80,302 were diagnosed with von Willebrand disease. In addition to these, increasing cases of surgeries are impelling the growth of the market as a lot of blood is lost during the operations, which increases the chances of needing transfusions. Also, the demand for blood transfusion rises in patients who are anemic. For instance, approximately 310 million major surgeries are performed every year globally, of which 50 million are in the USA, and 20 million are in Europe.

Increasing Adoption of Inorganic Growth Strategies

Various inorganic growth strategies such as mergers, collaborations, acquisitions, and partnerships are supporting the growth of the market. For instance, the Blood Center of Wisconsin collaborated with SysLogic Inc. to research how RFID technology can be utilized to heighten the safety of the patient while collecting and transfusing blood products. Similarly, in 2018, Invitrx Inc. launched a cord blood plasma product that contains plasticity-promoting proteins that may have anti-aging effects that increase neurogenesis and cognitive function.

Market Segmentation

The global blood & plasma components market is segmented into products, applications, end user, and company. Based on products, the market is divided into packed red blood cells, platelets products, frozen plasma, and plasma-derived products. Based on plasma-derived products, the market is further divided into immunoglobulins, albumins, coagulation factor concentrates, and others. Based on application, the market is divided into hematology, solid tumor management, and others. Based on hematology, the market is further divided into hemoglobinopathy, hematologic malignancies treatment, coagulopathy, and others. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of chronic diseases and surgeries in the country.

Market Players

CSL Limited, Grifols S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., and Versiti, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global blood & plasma components market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Blood & Plasma Components Market, By Products:

  • Packed Red Blood Cells
  • Platelets Products
  • Frozen Plasma
  • Plasma Derived Products
    • Immunoglobulins
    • Albumins
    • Coagulation Factor Concentrates
    • Others
    • Blood & Plasma Components Market, By Application:
  • Hematology
    • Hemoglobinopathy
    • Hematologic Malignancies Treatment
    • Coagulopathy
    • Others
  • Solid Tumor Management
  • Others

Blood & Plasma Components Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Blood & Plasma Components Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Blood & Plasma Components Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Blood & Plasma Components Market

5. Voice of Customer

6. Global Blood & Plasma Components Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 6.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 6.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 6.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 6.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 6.2.4. By Company (2021)
    • 6.2.5. By Region
  • 6.3. Market Map

7. North America Blood & Plasma Components Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 7.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 7.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 7.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 7.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Blood & Plasma Components Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Products
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. Canada Blood & Plasma Components Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Products
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Mexico Blood & Plasma Components Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Products
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User

8. Europe Blood & Plasma Components Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 8.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 8.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 8.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 8.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Blood & Plasma Components Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Products
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Blood & Plasma Components Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Products
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Blood & Plasma Components Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Products
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Blood & Plasma Components Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Products
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Blood & Plasma Components Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Products
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Asia-Pacific Blood & Plasma Components Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 9.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 9.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 9.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 9.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Blood & Plasma Components Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Products
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. India Blood & Plasma Components Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Products
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Japan Blood & Plasma Components Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Products
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User
    • 9.3.4. South Korea Blood & Plasma Components Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Products
        • 9.3.4.2.2. By Application
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Blood & Plasma Components Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Products
        • 9.3.5.2.2. By Application
        • 9.3.5.2.3. By End User

10. South America Blood & Plasma Components Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 10.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 10.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 10.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 10.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Blood & Plasma Components Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Products
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Blood & Plasma Components Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Products
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Blood & Plasma Components Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Products
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Middle East and Africa Blood & Plasma Components Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 11.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 11.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 11.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 11.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Blood & Plasma Components Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Products
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Blood & Plasma Components Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Products
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Blood & Plasma Components Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Products
        • 11.3.3.2.2. By Application
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. CSL Limited
  • 14.2. Grifols S.A.
  • 14.3. ADMA Biologics, Inc.
  • 14.4. Takeda Pharmaceutical Company Limited
  • 14.5. Octapharma AG
  • 14.6. Kedrion S.p.A
  • 14.7. Emergent BioSolutions Inc.
  • 14.8. Bio Products Laboratory Ltd.
  • 14.9. LFB S.A.
  • 14.10. Versiti, Inc.

15. Strategic Recommendations